NCT00401583 - A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2006

Primary Completion Date

February 20, 2008

Study Completion Date

February 20, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

GW786034 (pazopanib)

Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.

DRUG

Probe drugs

probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).

Trial Locations (2)

GSK Investigational Site, Singapore

GSK Investigational Site, Lebanon